Related Experiment Video
Updated: Feb 22, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Pomalidomide re-exposure after drug-related severe hypothyroidism: a case report
Francesca Bartolomei1, Tommaso Za1, Francesca Di Landro1
1Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
Abstract:
Pomalidomide, an analogue of lenalidomide and thalidomide, has shown significant activity in treating relapsed refractory multiple myeloma (MM). Due to its oral formulation and favorable safety profile, pomalidomide is generally well tolerated, even among elderly and frail patients. We present a case of severe hypothyroidism induced by pomalidomide in a 71-year-old woman with relapsing/refractory MM. After initiating levothyroxine therapy, her symptoms quickly resolved. We then attempted to resume pomalidomide treatment; the rechallenge proved safe concerning thyroid function. In conclusion, we recommend testing thyroid function in patients prior to and then every 2-3 months during pomalidomide treatment. If drug-induced hypothyroidism occurs, once the patient reaches a state of euthyroidism, a rechallenge can be considered with a good safety profile.
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Allergic Reactions
Drug Toxicity: Risk factors
Drug Toxicity: Dose-Dependent Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions

